O

Orphazyme A/S

12 employees

Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disorders called lysosomal storage diseases.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Diagnostics
Health Care
Heat-Shock Protein
Lysosomal Storage Diseases
Protein-Misfolding
Therapeutics
Genetics
Orphan Diseases
Orphan Drugs
Rare Disease

Date founded

2009

Funding rounds raised

Total raised

$95M

from 19 investors over 19 rounds

O

Orphazyme A/S raised $95M on November 24, 2017

Investors: EQT Life Sciences, Aescap, Novo Holdings, Idinvest Partners and Sunstone Life Science Ventures

O

Orphazyme A/S raised $15M on March 8, 2017

Investors: Aescap, Novo Holdings, Idinvest Partners, ALS Investment Fund and Sunstone Life Science Ventures

O

Orphazyme A/S raised $24M on January 9, 2015

Investors: Idinvest Partners, Aescap and Sunstone Life Science Ventures

O

Orphazyme A/S raised undisclosed on September 17, 2014

Investors: Wellcome Trust

O

Orphazyme A/S raised $20M on September 7, 2011

Investors: Aescap, Sunstone Life Science Ventures and Novo Holdings

O

Orphazyme A/S raised undisclosed on February 14, 2011

Investors: Novo Holdings and Sunstone Life Science Ventures

FAQ